Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 umbrella substudy of MK-5684 alone or with olaparib, docetaxel, or cabazitaxel in metastatic castration-resistant prostate cancer
MOH_2024-04-14_013330Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Merck & Co. Primary endpoints: Safety of MK-5684 alone and in combination and Recommended dose determination. Started Feb 2024; status: recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2024-04-14_013330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-14_013330.